baber/WOPTO huggingface dataset:
Patent NZ-526467-A (NZ)
Title: Therapeutic combination of amlodipine and benazepril/benazeprilat for treating hypertension, cardiocascular diseases and headaches
Inventor: COMFORT ANN REESE
IPC: A61P9/02
Filed: 2001-12-17
Abstract: A medicament comprising an angiotensin converting enzyme inhibitor (ACEI) selected from benazepril and benzaprilat and a calcium channel blocker, amlodipine, can be used in the manufacture of a medicament for treating or preventing hypertension congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood-pressure-related cerebrovascular disease, stroke, pulmonary disease, pulmonary hypertension and headache, wherein the amount of amlodipine corresponds to >10mg to 40mg of free base and the amount of the ACE inhibitor corresponds to 20mg to 160mg of benazepril hydrochloride. Also described are capsule formulations comprising a core comprising benzepril and a powder comprising amlodipine, methods of preparing pharmaceutical formulations of benazepril and amlodipine and methods of coating the core.
Patent NZ-526833-A (NZ)
Title: Electric heating/warming fabric articles
Inventor: ROCK MOSHE
IPC: D04B9/16
Filed: 2001-10-25
Abstract: A fabric article (10) that generates heat upon application of electrical power is formed, for example, by joining stitch and loop yarns to form a fabric body (12). An electrical resistance heating element (18) in the form of a conductive yarn is incorporated into the fabric body, the electrical resistance heating elements extending between opposite edge regions (20, 21) of the fabric. Conductive elements are provided for connecting the electrical resistance heating elements to a source of electrical power. (62) Divided out of 515050
Patent NZ-529065-A (NZ)
Title: Micro denier fiber fill insulation
Inventor: RUMIESZ JOSEPH
IPC: D04H1/4382
Filed: 2003-02-13
Abstract: Insulation or filling material composed of fiber balls comprising substantially round random entanglement of fibers which form fiber balls comprising micro denier fibers which are uncrimped and not bonded together are disclosed, wherein optionally the fibers may be siliconized, and optionally natural fibers or synthetic may also be mixed in the fiber balls.
Patent NZ-532259-A (NZ)
Title: Method for establishing a foundation in particular for a tower of a wind energy plant
Inventor: WOBBEN ALOYS
IPC: E02D27/32
Filed: 2002-09-24
Abstract: The invention relates to a method for establishing a foundation for a building comprising several segments, in particular for a tower of a wind energy plant, a foundation segment for use in such a method and wind energy plant. According to the invention, a stable foundation may be achieved whereby a method with the following method steps is disclosed: excavating a foundation bed, production of a stable essentially flat and horizontal-running granular sub-base in the foundation bed, placement of a foundation segment of the building on the granular sub-base, whereby at least three height-adjustable support rods are fixed to the foundation segment, by means of support feet on the end of each support rod, such that only the support rods are placed on given support points of the granular sub-base, production of reinforcing on the granular sub-base and casting what remains of the foundation bed with foundation masses, in particular, concrete up to above the lower edge of the foundation segment.
Patent NZ-534865-A (NZ)
Title: Stable adenoviral vectors and methods for propagation thereof
Inventor: VOGELS RONALD
IPC: A61K39/00
Filed: 2003-04-24
Abstract: Disclosed is a recombinant subgroup B adenovirus having a deletion in the E1-region and which adenovirus does not encode a functional E1B 55K gene product, said adenovirus comprising: (i) the adenovirus sequence located between the stop codon of the E1B 55K coding sequence and the start codon of the pIX coding sequence; and (ii) a functional pIX coding sequence under the control of a sequence having promoter activity, wherein said sequence having promoter activity consists of up to 0.7 kb of the adenovirus sequences that are directly upstream of the pIX start codon, said sequence comprising the minimally required sequence for promoter activity which is present within the last 166 bp of the E1B 55K coding sequence. Also disclosed is a recombinant subgroup B adenovirus comprising a functional pIX coding sequence and having a deletion in the E1-region, wherein the pIX coding sequence is under control of a heterologous promoter for driving expression in a given packaging cell.
Patent NZ-535165-A (NZ)
Title: Treatment of ophthalmic disorders using urea and urea derivatives
Inventor: KARAGEOZIAN VICKEN H
IPC: A61K31/407
Filed: 2003-02-13
Abstract: Disclosed is the use of compounds of formula I wherein R, R1-5, X, Y, m and n are as defined in the specification, for treatment of an opthalmological or nerve disorder.
Patent NZ-540266-A (NZ)
Title: Powder coating process
Inventor: KITTLE KEVIN JEFFREY
IPC: B05D1/24
Filed: 2003-12-11
Abstract: Disclosed is a process for forming a coating on a substrate, comprising: (a) establishing a fluidised-bed of a powder coating composition, thereby effecting tribostatic charging of the powder coating composition, the fluidised-bed including a fluidising chamber at least a part of which is conductive, (b) applying a voltage to the conductive part of the fluidising chamber, (c) immersing a substrate which is either electrically non-conductive or poorly conductive wholly or partly in the fluidised bed, whereby tribostatically charged particles of the powder coating composition adhere to the substrate, the substrate being either electrically isolated or earthed, (d) withdrawing the substrate from the fluidised bed, and (e) forming the adherent particles into a continuous coating over at least part of the substrate, the process being conducted without ionisation or corona effects in the fluidised bed.
Patent NZ-544305-A (NZ)
Title: Improved process for preparing alpha-polymorphic eletriptan hydrobromide
Inventor: FURLONG PATRICK JOSEPH
IPC: C07D403/06
Filed: 2004-07-12
Abstract: Disclosed is a process for preparing alpha-polymorphic eletriptan hydrobromide comprising the steps of (a) treating a solution of eletriptan in 2-butanone with hydrobromic acid and (b) distilling off a 2-butanone/water azeotrope until formation of anhydrous a-polymorphic eletriptan hydrobromide is complete.
Patent NZ-551399-A (NZ)
Title: Novel phenanthridine analogues and their uses as inhibitors of hyperproliferation of T cells and/or keratinocytes
Inventor: PEGORARO STEFANO
IPC: A61K31/473
Filed: 2004-10-05
Abstract: Disclosed are compounds of formula II, wherein X is C-R8, R19 is a polycyclic aromatic ring system, heteroaryl or cycloalkyl, and the remaining substituents are as defined in the specification. The compounds are useful in the treatment or prevention of diseases characterized by hyperproliferation of keratinocytes and/or T cells, such as psoriasis, atopic dermatitis, actinic keratoses, hyperkeratoses like epidermolytic hyperkeratosis, hyperkeratosis lenticularis perstans, keratosis pilaris and ichthyoses.
Patent NZ-552987-A (NZ)
Title: Light mounting for protecting lighting unit, formed by annular space between cap mounted to post
Inventor: BROADHURST ROBERT CHARLES
Filed: 2007-01-31
Abstract: The light mounting has a post with a head end and a foot end. A cap is located at the head end of the post, such that the cap has a side defining sleeve and defines an opening between cap and post in which a lighting unit may be mounted. The cap side is adapted to protect the lighting unit.
Patent NZ-566069-A (NZ)
Title: Azole and thiazole derivatives and their use
Inventor: RAY NICHOLAS CHARLES
IPC: C07D413/12
Filed: 2006-08-08
Abstract: Disclosed is a thiazole or oxazole derivative of formula (I), where the substituents are as defined in the specification. Also disclosed is the use of the compound for treating diseases and conditions in which M3 muscarinic receptor activity is implicated, such as a respiratory tract disorder, a gastrointestinal-tract disorder, a cardiovascular disorder, chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, bronchial hyperactivity, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis, irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal convulsions or hyperanakinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature, urinary-tract disorders accompanying micturition disorders including neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, motion sickness, and vagally induced sinus bradycardia.
Patent NZ-567499-A (NZ)
Title: A composition to be administered to a mammal or to a human being involving a protein element bound to a liposome
Inventor: GIL DANIEL SERRANO
IPC: A61K39/395
Filed: 2006-09-15
Abstract: Disclosed is a composition for administration to a mammal or human being, comprising at least one empty liposome capable of fusing with the membrane of a target cell or microorganism, wherein a structural protein element is bound to the liposome and defines an opening of considerable size in the liposome membrane, and the membrane of the liposome incorporates binding elements specific to the target cell or microorganism, wherein in use the liposome fuses with the membrane of the target cell or microorganism, and the opening defined by the structural protein element forms and maintains a drainage outlet in the membrane of the cell or micro-organism releasing the intracellular content into the extracellular medium.
Patent NZ-569015-A (NZ)
Title: Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as janus kinase inhibitors
Inventor: RODGERS JAMES D
IPC: A61K31/395
Filed: 2006-12-12
Abstract: Disclosed are heteroaryl substituted pyrrolopyrimidines represented by general formula (I), or pharmaceutical salts thereof. Also disclosed is the use of the compounds of formula (I) for the manufacture of a medicament for modulating an activity of a Janus kinase (JAK).
Patent NZ-569047-A (NZ)
Title: Steam floor mop with mop covered with cleaning cloth
Inventor: ZHOU HONG
IPC: A47L11/34
Filed: 2006-12-08
Abstract: A steam floor mop includes a handle, a main frame and a mop head that is connected movably with the main frame. In the main frame 1 are arranged a hand-operated water pump, a water tank and a vapour generator. The hand-operated water pump, the water tank, the vapour generator and the mop head are communicated with each other via pipelines. The handle is directly connected with the piston rod of the hand-operated water pump and controls the hand-operated water pump. The mop head typically has a brush and has an enveloping cleaning cloth.
Patent NZ-573003-A (NZ)
Title: Compositions and methods for the delivery of nitric oxide
Inventor: CARY STEPHEN P L
IPC: A61K38/42
Filed: 2007-05-21
Abstract: Disclosed is a pharmaceutical blood gas NO carrier composition comprising (i) a pharmaceutically acceptable amount of an H-NOX protein, wherein said H-NOX protein binds and delivers NO with minimal NO reactivity, and (ii) a pharmaceutically acceptable carrier, wherein either (a) wherein the koff, k1, or k2 for NO of the H-NOX protein is between 1 x 10-4s-1 and 10s-1 at 37 degrees C, and wherein the O2 dissociation constant of the H-NOX protein is at least 1ìM at 37 degrees C, or (b) wherein the NO dissociation constant of the H-NOX protein is within 2 orders of magnitude of that of human hemoglobin alpha, and wherein the NO reactivity of the H-NOX protein is at least 10-fold lower than that of human hemoglobin alpha.
Patent NZ-576365-A (NZ)
Title: Benzoylpyrazole compounds, process for their production and herbicides containing them
Inventor: KOMYOJI TERUMASA
IPC: A01N43/56
Filed: 2007-11-09
Abstract: Disclosed is a benzoylpyrazole compound represented by the formula (I) or its salt wherein R1 is alkyl, R2 is a hydrogen atom or alkyl, R3 is alkyl, R4 is alkyl or halogen, R5 is alkyl substituted by one of Y1, haloalkoxy, alkoxy substituted by one Y2, or alkoxycarbonyl, R6 is alkyl sulfonyl, A is alkylene substituted by at least one alkyl, Y1 is alkoxy or haloalkoxy, and Y2 is alkoxy.
Patent NZ-580462-A (NZ)
Title: injection device including means for adjusting the progression profile of the device
Inventor: WEBER WILFRIED
IPC: A61M5/20
Filed: 2008-06-03
Abstract: Disclosed is an injection device incorporating components whose relative movement causes an active substance to be injected. For this purpose, a receptacle (103), into and in which a carpule/syringe can be inserted and mounted, is retained in a housing (101). The receptacle can be moved by means of a carriage (108), and a plunger (104) that applies a force to the piston/s of the carpule/syringe. A traction rope which is deflected by means of a roll mounted on the carriage is provided for performing the pricking stroke, injection stroke, and retracting stroke. One end of the traction rope is connected to the receptacle while the other end thereof is connected to a tension spring (110) that is retained on the housing. Automatically and/or manually actuatable mechanisms between the housing, the receptacle, the plunger, and the carriage control the reciprocal coupling thereof to the traction rope. Thus the sequence of the pricking stroke, injection stroke, and retracting stroke and are fitted with at least one means that allows the user to adjust the progress profile of at least one of the strokes.
Patent NZ-586923-A (NZ)
Title: Methods and oligonucleotides for detection of mastitis causing bacteria
Inventor: HOLOPAINEN JANI
IPC: C12N15/11
Filed: 2008-12-31
Abstract: Disclosed is a method for determining the presence of mastitis causing bacteria in a milk sample comprising the steps of: a) isolating nucleic acid from a milk sample or a sample derived from milk; b) contacting the isolated nucleic acid obtained in step a) in a polymerase chain reaction mix with primers specifically hybridizing with the nucleic acid sequence of clumping factor gene of Staphylococcus aureus and amplifying at least part of the 95bp long amplicon in said clumping factor gene corresponding to nucleotides 534-628 in SEQ ID NO:8 and with primers specifically hybridizing with the nucleic acid sequence of elongation factor Tu gene of Staphylococcus spp. and amplifying at least part of the 119bp long amplicon in said elongation factor Tu gene corresponding to nucleotides 603-721 in SEQ ID NO:9; and c) performing a polymerase chain reaction with a reaction mix obtained from step b) so that the sequences of said clumping factor gene and elongation factor Tu gene are specifically amplified, if said sequences are present in the sample; d) detecting the presence of the amplified nucleid acid sequences, wherein the presence of amplified nucleic acid sequence from both clumping factor gene and elongation factor Tu gene is indicative of the presence of Staphylococcus aureus in the sample, and wherein the presence of amplified nucleic acid sequence from only elongation factor Tu gene is indicative of the presence of Staphylococcus spp. in the sample.
Patent NZ-592919-A (NZ)
Title: 3-aminocyclopentanecarboxamides as chemokine receptor modulators
Inventor: DEVRAJ RAJESH VENKATESWARAN
IPC: A61K31/407
Filed: 2009-11-20
Abstract: 592919 There is provided a compound of Formula I(a) or I(b) or a pharmaceutically acceptable salt thereof, wherein the various substituents are defined herein along with compositions comprising said compounds. Use of the compounds of any one or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating adisease associated with expression or activity of a chemokine receptor is also disclosed and the diseases that may be treated include: rheumatoid arthritis, atherosclerosis, lupus, multiple sclerosis, pain, transplant rejection, diabetes, liver fibrosis, viral disease, cancer, asthma, seasonal and perennial allergic rhinitis, sinusitis, conjunctivitis, age-related macular degeneration, food allergy, scombroid poisoning, psoriasis, undifferentiated spondyloarthropy, gout, urticaria, pruritus, eczema, inflammatory bowel disease, thrombotic disease, otitis media, fibrosis, liver cirrhosis, cardiac disease, Alzheimer's disease, sepsis, restenosis, Crohn's disease, ulcerative colitis, irritable bowel syndrome, hypersensitivity lung diseases, drug-induced pulmonary fibrosis, chronic obstructive pulmonary disease, arthritis, nephritis, atopic dermatitis, stroke, acute nerve injury, sarcoidosis, hepatitis, endometriosis, neuropathic pain, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity, interstitial lung disease, eye disorders or obesity.
Patent NZ-600596-A (NZ)
Title: Dose setting mechanism with maximum dose limiting element
Inventor: SMITH CHRISTOPHER JAMES
IPC: A61M5/315
Filed: 2010-12-16
Abstract: 600596 A drug delivery device comprising a dose setting mechanism, where the mechanism comprises first maximum dose stop features 1 on a first component part 2 of the drug delivery device, corresponding second maximum dose stop features 3 on a second component part 4 of the drug delivery device, with the first and second maximum dose stop features 1, 3 being designed to limit a relative rotational movement between the first and second component parts 2, 4. A maximum dose stop is determined by the first and second maximum dose stop features rotationally moving towards one another and making contact when the maximum dose is reached.A maximum dose limiting device 5, which is a maximum dose limiting sleeve, is interposed on the first component part 2 between said first and second maximum dose stop features and has mating features on a first end fitting to the first maximum dose stop feature 1 and replica stop features on a second end replicating the first maximum dose stop features.
Patent NZ-602542-A (NZ)
Title: Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
Inventor: BONNERT ROGER VICTOR
IPC: C07D519/00
Filed: 2008-01-10
Abstract: Disclosed is a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state. For example N-{ cis-4-[6-fluoro-1-{ 4’-[(4-methyl-1,4-diazepan-1-yl)methyl]biphenyl-3-yl} -2,4-dioxo-1,4-dihydropyrido[2,3-d]pyrimidin-3(2H)-yl]cyclohexyl} -N2,N2-dimethylglycinamide.
Patent NZ-603723-A (NZ)
Title: Guy anchor reinforcement
Inventor: REYES JAIME
IPC: E02D5/80
Filed: 2011-04-20
Abstract: Disclosed is a reinforcing system (200) for a guy anchor of a guyed tower or additionally guyed tower having an anchor head (114) and an anchor shaft (116) extending from the anchor head (114) into the ground. The reinforcing system (200) provides additional support to the guy anchor head (114) and anchor shaft (116). The reinforcing system (200) comprises a solid structure (210); a supplemental anchor shaft (220) and a retaining structure. The solid structure (210) is disposed around a portion of the anchor shaft (116). The solid structure (210) includes a top surface (210f); a front wall portion (210g); a back wall portion (210h) and a middle portion. The top surface (210f) is disposed above the ground. The front wall portion (210g) faces the tower and extends below the top surface (210f) into the ground. The back wall portion (210h) extends below the top surface (210f) into the ground. The middle portion is disposed between the front wall portion (210g) and the back wall portion (210h). The front (210g) and back (210h) wall portions extend more deeply into the ground than the middle portion. The supplemental anchor shaft (220) is attached to the anchor head (114) and extends into the solid structure (210). The retaining structure is attached to or is integral with the supplemental anchor shaft (220) within the solid structure (210).
Patent NZ-611026-A (NZ)
Title: Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
Inventor: GUITTET CATHERINE
IPC: A61K9/28
Filed: 2011-11-18
Abstract: Provided is a solid oral pharmaceutical composition comprising two tablet formulations. The first tablet formulation, in the form of at least one micro-tablet, comprises a core comprising at least one Krebs cycle precursor salt and a coating comprising at least one coating agent. The second tablet formulation, in the form of at least one mini-tablet, comprises a core comprising at least one bicarbonate salt and at least one sustained-release hydrophilic matrix and a coating comprising at least one coating agent. A preferred Krebs cycle precursor salt is potassium citrate. A preferred bicarbonate salt is potassium bicarbonate. Further provided is the use of the pharmaceutical composition as a medicament, in particular in the treatment and/or prevention of cystinuria.
Patent NZ-612989-A (NZ)
Title: Production method for particle board and fiber board
Inventor: UMEMURA KENJI
IPC: B27N3/04
Filed: 2011-11-07
Abstract: The disclosure relates to a method for manufacturing particleboard or fibre board comprising a step of adding a polycarboxylic acid to plant-derived matter that has been turned into small pieces or fibre, and further comprising a step of adding one or more isocyanate group-containing compound having two or more isocyanate groups in a molecule to the composition, wherein the weight ration of the plant derived matter to the isocyanate group-containing compound is 100:0.1 to 100:3.0. The method may include hot press step and may further include the addition of a sugar. The polycarboxylic acid may be citric acid, itaconic acid or malic acid and the sugar may be sucrose, xylose or dextrin.
Patent NZ-615332-A (NZ)
Title: Method, system and apparatus for use in locating subsurface ore bodies
Inventor: STEPHEN COOTE
IPC: G01V9/00
Filed: 2012-02-24
Abstract: A method and system for locating subsurface ore bodies. Samples of near surface soil are collected over a predetermined geographical area. The samples are analysed to discover any chemical anomalies in the dust particles as a way of identifying possible subcropping mineralization. A tine (22) and collection tube (24) engage into subsurface soil and samples are drawn up the tube into a dust collection module (12). Sub 5 micron particles are captured on an electrostatically charged tape (within 12, not shown). Consecutive samples are indexed on the tape e.g. with a barcode. Collected dust samples are ablated by a laser ablation cell and the ablated sample analysed by a mass spectrometer for presence of ions indicating presence of a resource body, such as a body of ore, minerals or hydrocarbons.
Patent NZ-620048-A (NZ)
Title: 2,5-disubstituted arylsulfonamide ccr3 antagonists
Inventor: BAAUM ERIK DEAN
IPC: C07D487/04
Filed: 2010-04-21
Abstract: Disclosed herein is a compound of formula (II), wherein the variables are defined in the specification, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and the use thereof in the treatment of CCR3-mediated, eosinophil-related, basophil-related or mast cell-related disorder, disease or condition, such as asthma, exercise induced asthma, allergic rhinitis, atopic dermatitis, chronic obstructive pulmonary disease, or allergic conjunctivitis. Compounds of the disclosure include: 4-(2,5-dimethylphenoxy)-3-(piperazin-1-ylsulfonyl)benzonitrile